Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a leading global provider of specialty medical devices for critical care and surgical procedures. Headquartered in Wayne, Pennsylvania, Teleflex employs approximately 12,000 people worldwide and serves healthcare providers in more than 150 countries.
The company’s diverse product portfolio spans across several key segments: vascular access, interventional, anesthesia, surgical, interventional urology, original-equipment manufacturing, and others. These segments collectively cover a wide range of medical needs, from complex surgical interventions to everyday critical care requirements.
Teleflex’s vascular access segment, contributing 24% to 2023 sales, includes innovative solutions for secure and reliable bloodstream access. The interventional segment, accounting for 17%, focuses on cutting-edge devices for minimally invasive procedures. Anesthesia and surgical segments, with 13% and 14% of sales respectively, offer advanced tools and technologies to improve patient outcomes during surgeries.
The company’s interventional urology segment, noted for its UroLift™ System, addresses benign prostatic hyperplasia (BPH) with minimally invasive solutions that preserve patient quality of life. Original-equipment manufacturing and other segments contribute 11% and 10% of sales respectively, underscoring Teleflex’s broad manufacturing capabilities and diverse product offerings.
Teleflex's geographic exposure is primarily in the United States, which generates 60% of its revenue, with international markets contributing the remainder. The company’s global reach and diverse product lines highlight its significant impact on the healthcare industry worldwide.
In recent years, Teleflex has achieved notable success with a 6.5% constant currency revenue growth in 2023, driven by the expansion of its geographic presence and the launch of innovative new products. The company has strategically acquired Palette Life Sciences AB, enhancing its portfolio and operational efficiencies.
Teleflex remains committed to its mission of providing solutions that improve outcomes and enhance safety for patients and healthcare providers. By leveraging purpose-driven innovation, Teleflex continues to address unmet clinical needs and advance healthcare technologies.
For more information about Teleflex and its comprehensive product offerings, please visit teleflex.com.
Teleflex Incorporated (NYSE: TFX) announced that Chairman, President, and CEO Liam Kelly will speak at the Raymond James 42nd Annual Institutional Investors Conference on March 2, 2021, at 12:30 p.m. ET. A live audio webcast and accompanying slides will be accessible on the investor section of Teleflex's website. Teleflex is dedicated to enhancing healthcare through innovative medical technologies across various specialties.
Teleflex Incorporated (NYSE: TFX) will announce its Q4 2020 and full-year financial results on February 25, 2021, before market open. A live conference call will occur at 8:00 a.m. ET on the same day, accessible via audio webcast on the company’s website. An audio replay will be available from 11:00 a.m. ET on February 25, 2021, until 11:00 a.m. ET on March 2, 2021. Teleflex is a leading provider of medical technologies aimed at enhancing health and quality of life.
Teleflex Incorporated (NYSE: TFX) announced new data published in European Urology Focus, indicating that the Prostatic Urethral Lift (PUL) procedure using the UroLift® System significantly preserves and improves sexual function compared to medical treatment for benign prostatic hyperplasia (BPH). The study showed a 17% and 21% increase in erectile function at 1 and 2 years, respectively, and substantial improvements in ejaculatory function over four years. Meanwhile, medication treatments generally led to declines in sexual function. These findings underscore UroLift's benefits for BPH patients.
Teleflex expands its ErgoPack® Complete system by introducing new Arrow® Multi-Lumen Access Catheter (MAC) and Percutaneous Sheath Introducer (PSI) systems, enhancing vascular access solutions. Building on the October 2020 launch of the ErgoPack® Complete CVC System, these innovations incorporate clinician-inspired features such as a GlideWheel™ Advancer and kink-resistant guidewire. These enhancements aim to reduce catheter-related complications, adhering to CDC and SHEA guidelines while offering broad-spectrum antimicrobial protection against pathogens.
Teleflex, a global medical technology provider, announced that its Chairman and CEO, Liam Kelly, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 8:20 a.m. ET. An audio webcast and slide presentation will be accessible on the investor section of the Teleflex website. Teleflex focuses on innovative healthcare solutions in various fields, including vascular access, anesthesia, and emergency medicine, aiming to improve the lives of patients and healthcare providers.
DW Healthcare Partners has successfully closed the sale of Z-Medica to Teleflex (NYSE: TFX). Z-Medica specializes in manufacturing hemostatic products crucial for controlling bleeding. DWHP initially invested in Z-Medica in 2012, significantly growing the business through product development and channel diversification. This sale follows Z-Medica's successful evolution into a major player in the hemostatic market, largely attributed to strategic partnerships and innovative products like QuickClot Control+®.
Teleflex (NYSE:TFX) has successfully completed the acquisition of Z-Medica for $500 million, with a potential additional $25 million based on performance milestones. This strategic buy aims to enhance Teleflex's medical technology portfolio, specifically in hemorrhage control products, which are critical for healthcare providers. The acquisition is not anticipated to have a significant impact on 2020 revenue but is expected to contribute between $60 million and $70 million in revenue and $0.07 to $0.15 in adjusted EPS for 2021, with potential for high-single digit growth thereafter.
Teleflex Incorporated has been recognized as one of the best places to work in medical sales for the fourth consecutive year, according to MedReps.com’s 2021 survey. Teleflex ranked first in the Large Category for Best Medical Device Companies and second overall among medical sales companies. The survey, which included over 2,000 respondents, highlights the company's positive corporate culture and commitment to employee welfare during the COVID-19 pandemic. Teleflex emphasizes innovation and values that prioritize both patient care and employee experience.
Teleflex announced positive results from four studies on the UroLift System for treating benign prostatic hyperplasia (BPH) at the ICS 2020 Annual Meeting. These studies confirm the safety and efficacy of the UroLift System, demonstrating significant symptom improvement for men suffering from BPH. With over 40% of men over 50 affected by BPH, the treatment is becoming a preferred option. Key findings included high catheter independence rates (86%-87%) and notable symptom relief, reinforcing the UroLift System as a minimally invasive solution that maintains sexual function.
FAQ
What is the current stock price of Teleflex (TFX)?
What is the market cap of Teleflex (TFX)?
What does Teleflex Incorporated do?
Where is Teleflex Incorporated headquartered?
How many people does Teleflex employ?
What are the main segments of Teleflex's business?
What percentage of Teleflex’s revenue comes from the United States?
What recent acquisitions has Teleflex made?
What is the UroLift™ System?
What was Teleflex's revenue growth in 2023?
How can one access Teleflex's investor conference calls?
What is the mission of Teleflex Incorporated?
